# Microbiological Quality Considerations in Non-Sterile Drug Manufacturing: Draft Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/microbiological-quality-considerations-in-non-sterile-drug-manufacturing-draft-guidance-for-industry/37a0a205-577b-4738-a343-eec1075de07d

> FDA guidance document: Microbiological Quality Considerations in Non-Sterile Drug Manufacturing: Draft Guidance for Industry. Issue date: September 29, 2021. Get complete insights and analysis.

---

## Details

- Title: Microbiological Quality Considerations in Non-Sterile Drug Manufacturing: Draft Guidance for Industry
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2021-09-29
- Comment Close Date: 2021-12-29
- Last Changed: 2021-10-14
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2021-D-0432">FDA-2021-D-0432</a>

## Related Documents

- [Establishing Impurity Specifications for Antibiotics](https://www.globalkeysolutions.net/guidances/guidance-document/establishing-impurity-specifications-for-antibiotics/5bb8badb-7c32-4b76-bfc9-bbb8ab55fb84)
- [Clinical Pharmacology Considerations for Peptide Drug Products](https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacology-considerations-for-peptide-drug-products/1609c8ed-4d50-4235-8a00-9c63176affe8)
- [Using the Inactive Ingredient Database Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/using-the-inactive-ingredient-database-guidance-for-industry/0bf5000a-4dfb-4c0c-b619-fdb0e028ed1d)